Literature DB >> 21270218

Disseminated fusariosis occurring in two patients despite posaconazole prophylaxis.

Prithviraj Bose1, Hiral D Parekh, Jennifer L Holter, Ronald A Greenfield.   

Abstract

Posaconazole is widely used for prophylaxis against invasive fungal infections in patients undergoing myeloablative therapy. Disseminated fusariosis is a serious invasive mold infection in such patients. Preclinical and clinical studies indicate activity of posaconazole against Fusarium. We describe two cases of disseminated fusariosis that occurred despite posaconazole prophylaxis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21270218      PMCID： PMC3122782          DOI： 10.1128/JCM.02325-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

2.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

Review 3.  Prevention and treatment of cancer-related infections.

Authors:  Brahm H Segal; Alison G Freifeld; Lindsey Robert Baden; Arthur E Brown; Corey Casper; Erik Dubberke; Michael Gelfand; John N Greene; Michael G Ison; James I Ito; Judith E Karp; Daniel R Kaul; Earl King; Emily Mackler; Guido Marcucci; Jose G Montoya; Ashley Morris Engemann; Ken Rolston; Angelina S The
Journal:  J Natl Compr Canc Netw       Date:  2008-02       Impact factor: 11.908

4.  Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection.

Authors:  Roshan Lewis; Holly Hogan; Allan Howell; Amar Safdar
Journal:  Leuk Lymphoma       Date:  2008-01

Review 5.  Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.

Authors:  Johan Maertens
Journal:  Eur J Haematol       Date:  2007-01-23       Impact factor: 2.997

6.  Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.

Authors:  Issam I Raad; Ray Y Hachem; Raoul Herbrecht; John R Graybill; Roberta Hare; Gavin Corcoran; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-04-11       Impact factor: 9.079

Review 7.  Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Epidemiology of invasive mycoses in North America.

Authors:  Michael A Pfaller; Daniel J Diekema
Journal:  Crit Rev Microbiol       Date:  2010       Impact factor: 7.624

9.  Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection.

Authors:  Marcio Nucci; Elias J Anaissie; Flavio Queiroz-Telles; Carlos A Martins; Plínio Trabasso; Cristiana Solza; Claudia Mangini; Belinda P Simões; Arnaldo L Colombo; Jorge Vaz; Carlos E Levy; Silvia Costa; Vaneusa A Moreira; José Salvador Oliveira; Nestor Paraguay; Gisele Duboc; Julio C Voltarelli; Angelo Maiolino; Ricardo Pasquini; Cármino A Souza
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

Review 10.  Fusarium infections in immunocompromised patients.

Authors:  Marcio Nucci; Elias Anaissie
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132
View more
  7 in total

1.  Skin nodules in a patient with acute lymphoblastic leukaemia.

Authors:  Lenaïg Le Clech; Pascal Hutin; Solène Le Gal; Gaëlle Guillerm
Journal:  BMJ Case Rep       Date:  2014-01-09

2.  Disseminated fusariosis with cutaneous involvement in hematologic malignancies: report of six cases with high mortality rate.

Authors:  Marina Zoéga Hayashida; Camila Arai Seque; Milvia Maria Simões E Silva Enokihara; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.896

Review 3.  Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective.

Authors:  Michel Laverdiere; Eric J Bow; Coleman Rotstein; Julie Autmizguine; Raewyn Broady; Gary Garber; Shariq Haider; Trana Hussaini; Shahid Husain; Philippe Ovetchkine; Jack T Seki; Yves Théorêt
Journal:  Can J Infect Dis Med Microbiol       Date:  2014 Nov-Dec       Impact factor: 2.471

Review 4.  Fusarium infection: report of 26 cases and review of 97 cases from the literature.

Authors:  Maged Muhammed; Theodora Anagnostou; Athanasios Desalermos; Themistoklis K Kourkoumpetis; Herman A Carneiro; Justin Glavis-Bloom; Jeffrey J Coleman; Eleftherios Mylonakis
Journal:  Medicine (Baltimore)       Date:  2013-11       Impact factor: 1.889

5.  Fusarium napiforme systemic infection: case report with molecular characterization and antifungal susceptibility tests.

Authors:  Marcela de Souza; Tetsuhiro Matsuzawa; Luzia Lyra; Ariane Fidelis Busso-Lopes; Tohru Gonoi; Angélica Zaninele Schreiber; Katsuhiko Kamei; Maria Luiza Moretti; Plínio Trabasso
Journal:  Springerplus       Date:  2014-08-30

Review 6.  Reduced Multidrug Susceptibility Profile Is a Common Feature of Opportunistic Fusarium Species: Fusarium Multi-Drug Resistant Pattern.

Authors:  Saad J Taj-Aldeen
Journal:  J Fungi (Basel)       Date:  2017-04-10

7.  The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study

Authors:  Vildan Özkocaman; Fahir Özkalemkaş; Serdar Seyhan; Beyza Ener; Ahmet Ursavaş; Tuba Ersal; Esra Kazak; Ezgi Demirdöğen; Reşit Mıstık; Halis Akalın
Journal:  Turk J Haematol       Date:  2018-07-26       Impact factor: 1.831
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.